Skip to main content
Top
Gepubliceerd in:

11-03-2017

Differential impact of systemic lupus erythematosus and rheumatoid arthritis on health-related quality of life

Auteurs: Benjamin Chaigne, Axel Finckh, Deshire Alpizar-Rodriguez, Delphine Courvoisier, Camillo Ribi, Carlo Chizzolini, For The Swiss Clinical Quality Management Program For Rheumatoid Arthritis, The Swiss Systemic Lupus Erythematosus Cohort Study Group

Gepubliceerd in: Quality of Life Research | Uitgave 7/2017

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

This study examined and compared health-related quality of life (QoL) in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Methods

We included patients from two multicentric cohorts, the Swiss SLE cohort study (SSCS) and the Swiss Clinical Quality Management Program for RA (SCQM-RA). Patients were matched by age, sex and disease duration using the propensity score. Disease activity was assessed by SELENA-SLEDAI in SLE and by DAS-28 in RA. QoL was captured by the short-form 36 (SF-36). The primary outcomes were physical component summary (PCS) and mental component summary (MCS) of the SF-36. Generalized estimating equation models were used to assess evolution over time.

Results

We analyzed 267 SLE patients and 267 matched RA patients. More patients with RA had active disease and more patients with SLE had immunosuppressant therapies at baseline. The median [interquartile range (IQR)] MCS and PCS scores were 45.1 [33.7–52.6] and 45.6 [38.0–53.0] in SLE and 48.8 [37.6–56.7] and 34.7 [26.8–43.0] in RA, respectively (ps < 0.001). Over one year the differences persisted, although PCS and MCS increased in RA (ps < 0.001) but not in SLE in the univariate analysis. The differences in MCS and PCS scores between RA and SLE remained qualitatively similar after adjustment for patient characteristics, treatment, and activity disease.

Conclusions

SLE and RA both affect QoL. Patients with SLE have lower MCS, whereas patients with RA have lower PCS. These differences remained over 1 year of follow up, suggesting fundamental dissimilarities between SLE and RA in their impact on QoL.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference Tani, C., D’Aniello, D., Delle Sedie, A., Carli, L., Cagnoni, M., Possemato, N., et al. (2013). Rhupus syndrome: Assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients. Autoimmunity Reviews, 12(4), 537–541.CrossRefPubMed Tani, C., D’Aniello, D., Delle Sedie, A., Carli, L., Cagnoni, M., Possemato, N., et al. (2013). Rhupus syndrome: Assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients. Autoimmunity Reviews, 12(4), 537–541.CrossRefPubMed
2.
go back to reference Lisnevskaia L, Murphy G, Isenberg D, (2014). Systemic lupus erythematosus. Lancet, 384, 1878–1888.CrossRefPubMed Lisnevskaia L, Murphy G, Isenberg D, (2014). Systemic lupus erythematosus. Lancet, 384, 1878–1888.CrossRefPubMed
3.
go back to reference Scott, D. L., Wolfe, F., Huizinga, T. W. J. (2010). Rheumatoid arthritis. Lancet, 376(9746), 1094–1108.CrossRefPubMed Scott, D. L., Wolfe, F., Huizinga, T. W. J. (2010). Rheumatoid arthritis. Lancet, 376(9746), 1094–1108.CrossRefPubMed
4.
go back to reference Strand, V., Levy, R. A., Cervera, R., Petri, M. A., Birch, H., Freimuth, W. W., et al. (2014). Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Annals of the Rheumatic Diseases, 73(5), 838–844.CrossRefPubMed Strand, V., Levy, R. A., Cervera, R., Petri, M. A., Birch, H., Freimuth, W. W., et al. (2014). Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Annals of the Rheumatic Diseases, 73(5), 838–844.CrossRefPubMed
5.
go back to reference Bingham, C. O., Weinblatt, M., Han, C., Gathany, T. A., Kim, L., Lo, K. H., et al. (2014). The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial. The Journal of Rheumatology, 41(6), 1067–1076.CrossRefPubMed Bingham, C. O., Weinblatt, M., Han, C., Gathany, T. A., Kim, L., Lo, K. H., et al. (2014). The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial. The Journal of Rheumatology, 41(6), 1067–1076.CrossRefPubMed
6.
go back to reference Ware, J. E., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.CrossRefPubMed Ware, J. E., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.CrossRefPubMed
7.
go back to reference Linde, L., Sørensen, J., Ostergaard, M., Hørslev-Petersen, K., & Hetland, M. L. (2008). Health-related quality of life: validity, reliability, and responsiveness of SF-36, 15D, EQ-5D [corrected] RAQoL, and HAQ in patients with rheumatoid arthritis. The Journal of Rheumatology, 35(8), 1528–1537.PubMed Linde, L., Sørensen, J., Ostergaard, M., Hørslev-Petersen, K., & Hetland, M. L. (2008). Health-related quality of life: validity, reliability, and responsiveness of SF-36, 15D, EQ-5D [corrected] RAQoL, and HAQ in patients with rheumatoid arthritis. The Journal of Rheumatology, 35(8), 1528–1537.PubMed
8.
go back to reference Stoll, T., Gordon, C., Seifert, B., Richardson, K., Malik, J., Bacon, P. A., et al. (1997). Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. The Journal of Rheumatology, 24(8), 1608–1614.PubMed Stoll, T., Gordon, C., Seifert, B., Richardson, K., Malik, J., Bacon, P. A., et al. (1997). Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. The Journal of Rheumatology, 24(8), 1608–1614.PubMed
9.
go back to reference Matcham F, Scott IC, Rayner L, Hotopf M, Kingsley GH, Norton S, et al. (2014). The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 44, 123–130.CrossRefPubMed Matcham F, Scott IC, Rayner L, Hotopf M, Kingsley GH, Norton S, et al. (2014). The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 44, 123–130.CrossRefPubMed
10.
go back to reference Mok, C. C., Ho, L. Y., Cheung, M. Y., Yu, K. L., & To, C. H. (2009). Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: A 2-year prospective study. Scandinavian Journal of Rheumatology, 38(2), 121–127.CrossRefPubMed Mok, C. C., Ho, L. Y., Cheung, M. Y., Yu, K. L., & To, C. H. (2009). Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: A 2-year prospective study. Scandinavian Journal of Rheumatology, 38(2), 121–127.CrossRefPubMed
11.
go back to reference Zhu, T. Y., Tam, L.-S., Lee VWY, Lee, K. K., & Li, E. K. (2010). Relationship between flare and health-related quality of life in patients with systemic lupus erythematosus. The Journal of Rheumatology, 37(3), 568–573.CrossRefPubMed Zhu, T. Y., Tam, L.-S., Lee VWY, Lee, K. K., & Li, E. K. (2010). Relationship between flare and health-related quality of life in patients with systemic lupus erythematosus. The Journal of Rheumatology, 37(3), 568–573.CrossRefPubMed
12.
go back to reference Urowitz, M., Gladman, D. D., Ibañez, D., Sanchez-Guerrero, J., Bae, S. C., Gordon, C., et al. (2014). Changes in quality of life in the first 5 years of disease in a multicenter cohort of patients with systemic lupus erythematosus. Arthritis Care and Research, 66(9), 1374–1379.CrossRefPubMed Urowitz, M., Gladman, D. D., Ibañez, D., Sanchez-Guerrero, J., Bae, S. C., Gordon, C., et al. (2014). Changes in quality of life in the first 5 years of disease in a multicenter cohort of patients with systemic lupus erythematosus. Arthritis Care and Research, 66(9), 1374–1379.CrossRefPubMed
13.
go back to reference Benitha, R., & Tikly, M. (2007). Functional disability and health-related quality of life in South Africans with rheumatoid arthritis and systemic lupus erythematosus. Clinical Rheumatology, 26(1), 24–29.CrossRefPubMed Benitha, R., & Tikly, M. (2007). Functional disability and health-related quality of life in South Africans with rheumatoid arthritis and systemic lupus erythematosus. Clinical Rheumatology, 26(1), 24–29.CrossRefPubMed
14.
go back to reference Kumar, K., Gordon, C., Toescu, V., Buckley, C. D., Horne, R., Nightingale, P. G., et al. (2008). Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: A comparison between patients of South Asian and White British origin. Rheumatology, 47(5), 690–697.CrossRefPubMed Kumar, K., Gordon, C., Toescu, V., Buckley, C. D., Horne, R., Nightingale, P. G., et al. (2008). Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: A comparison between patients of South Asian and White British origin. Rheumatology, 47(5), 690–697.CrossRefPubMed
15.
go back to reference Wolfe, F., Michaud, K., Li, T., & Katz, R. S. (2010). EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus: Comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, and fibromyalgia. The Journal of Rheumatology, 37(2), 296–304.CrossRefPubMed Wolfe, F., Michaud, K., Li, T., & Katz, R. S. (2010). EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus: Comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, and fibromyalgia. The Journal of Rheumatology, 37(2), 296–304.CrossRefPubMed
16.
go back to reference Hanly, J. G., Fisk, J. D., McCurdy, G., Fougere, L., & Douglas, J.-A. (2005). Neuropsychiatric syndromes in patients with systemic lupus erythematosus and rheumatoid arthritis. The Journal of Rheumatology, 32(8), 1459–1466.PubMed Hanly, J. G., Fisk, J. D., McCurdy, G., Fougere, L., & Douglas, J.-A. (2005). Neuropsychiatric syndromes in patients with systemic lupus erythematosus and rheumatoid arthritis. The Journal of Rheumatology, 32(8), 1459–1466.PubMed
17.
go back to reference Gilboe, I. M., Kvien, T. K., & Husby, G. (1999). Health status in systemic lupus erythematosus compared to rheumatoid arthritis and healthy controls. The Journal of Rheumatology, 26(8), 1694–1700.PubMed Gilboe, I. M., Kvien, T. K., & Husby, G. (1999). Health status in systemic lupus erythematosus compared to rheumatoid arthritis and healthy controls. The Journal of Rheumatology, 26(8), 1694–1700.PubMed
18.
go back to reference Ribi, C., Trendelenburg, M., Gayet-Ageron, A., Cohen, C., Dayer, E., Eisenberger, U., et al. (2014). The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland. Swiss Medical Weekly, 144, w13990.PubMed Ribi, C., Trendelenburg, M., Gayet-Ageron, A., Cohen, C., Dayer, E., Eisenberger, U., et al. (2014). The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland. Swiss Medical Weekly, 144, w13990.PubMed
19.
go back to reference Hochberg, M. C. (1997). Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism, 40(9), 1725.CrossRefPubMed Hochberg, M. C. (1997). Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism, 40(9), 1725.CrossRefPubMed
20.
go back to reference Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., McShane, D. J., Rothfield, N. F., et al. (1982). The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism, 25(11), 1271–1277.CrossRefPubMed Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., McShane, D. J., Rothfield, N. F., et al. (1982). The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism, 25(11), 1271–1277.CrossRefPubMed
21.
go back to reference McHorney, C. A., Ware, J. E., Lu, J. F., & Sherbourne, C. D. (1994). The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Medical Care, 32(1), 40–66.CrossRefPubMed McHorney, C. A., Ware, J. E., Lu, J. F., & Sherbourne, C. D. (1994). The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Medical Care, 32(1), 40–66.CrossRefPubMed
22.
go back to reference Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. (2005). Combined oral contraceptives in women with systemic lupus erythematosus. The New England Journal of Medicine, 353(24), 2550–2558.CrossRefPubMed Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. (2005). Combined oral contraceptives in women with systemic lupus erythematosus. The New England Journal of Medicine, 353(24), 2550–2558.CrossRefPubMed
23.
go back to reference Yee, C.-S., Farewell, V. T., Isenberg, D. A., Griffiths, B., Teh, L.-S., Bruce, I. N., et al. (2011). The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology, 50(5), 982–988.CrossRefPubMed Yee, C.-S., Farewell, V. T., Isenberg, D. A., Griffiths, B., Teh, L.-S., Bruce, I. N., et al. (2011). The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology, 50(5), 982–988.CrossRefPubMed
24.
go back to reference Anderson, J., Caplan, L., Yazdany, J., Robbins, M. L., Neogi, T., Michaud, K., et al. (2012). Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care and Research, 64(5), 640–647.CrossRefPubMedPubMedCentral Anderson, J., Caplan, L., Yazdany, J., Robbins, M. L., Neogi, T., Michaud, K., et al. (2012). Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care and Research, 64(5), 640–647.CrossRefPubMedPubMedCentral
25.
go back to reference Kiely, P., Walsh, D., Williams, R., Young, A., Early Rheumatoid Arthritis Network (2011). Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity–the early RA network (ERAN). Rheumatology, 50(5), 926–931.CrossRefPubMed Kiely, P., Walsh, D., Williams, R., Young, A., Early Rheumatoid Arthritis Network (2011). Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity–the early RA network (ERAN). Rheumatology, 50(5), 926–931.CrossRefPubMed
26.
go back to reference Fransen, J., Creemers, M. C. W., & Van Riel, P. L. C. M. (2004). Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology, 43(10), 1252–1255.CrossRefPubMed Fransen, J., Creemers, M. C. W., & Van Riel, P. L. C. M. (2004). Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology, 43(10), 1252–1255.CrossRefPubMed
27.
go back to reference van Gestel, A. M., Haagsma, C. J., & van Riel, P. L. (1998). Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis and Rheumatism, 41(10), 1845–1850.CrossRefPubMed van Gestel, A. M., Haagsma, C. J., & van Riel, P. L. (1998). Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis and Rheumatism, 41(10), 1845–1850.CrossRefPubMed
28.
go back to reference Welsing PMJ, Landewé RBM, van Riel PLCM, Boers, M., van Gestel, A. M., van der Linden, S., et al. (2004). The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis and Rheumatism, 50(7), 2082–2093.CrossRefPubMed Welsing PMJ, Landewé RBM, van Riel PLCM, Boers, M., van Gestel, A. M., van der Linden, S., et al. (2004). The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis and Rheumatism, 50(7), 2082–2093.CrossRefPubMed
29.
go back to reference Gladman, D. D., Urowitz, M. B., Kagal, A., & Hallett, D. (2000). Accurately describing changes in disease activity in Systemic Lupus Erythematosus. The Journal of Rheumatology, 27(2), 377–379.PubMed Gladman, D. D., Urowitz, M. B., Kagal, A., & Hallett, D. (2000). Accurately describing changes in disease activity in Systemic Lupus Erythematosus. The Journal of Rheumatology, 27(2), 377–379.PubMed
30.
go back to reference Yee, C.-S., Cresswell, L., Farewell, V., Rahman, A., Teh, L.-S., Griffiths, B., et al. (2010). Numerical scoring for the BILAG-2004 index. Rheumatology, 49(9), 1665–1669.CrossRefPubMedPubMedCentral Yee, C.-S., Cresswell, L., Farewell, V., Rahman, A., Teh, L.-S., Griffiths, B., et al. (2010). Numerical scoring for the BILAG-2004 index. Rheumatology, 49(9), 1665–1669.CrossRefPubMedPubMedCentral
31.
go back to reference Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, et al. (2009). Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheumatology, 61(9), 1143–1151.CrossRef Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, et al. (2009). Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheumatology, 61(9), 1143–1151.CrossRef
32.
go back to reference Wallace, D. J., Stohl, W., Furie, R. A., Lisse, J. R., McKay, J. D., Merrill, J. T., et al. (2009). A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheumatology, 61(9), 1168–1178.CrossRef Wallace, D. J., Stohl, W., Furie, R. A., Lisse, J. R., McKay, J. D., Merrill, J. T., et al. (2009). A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheumatology, 61(9), 1168–1178.CrossRef
33.
go back to reference Rosenbaum, P. R., Rubin, D. B. (1983). The central role of the propensity score in observational studies for causal effects. Biometrika, 70(1), 41–55.CrossRef Rosenbaum, P. R., Rubin, D. B. (1983). The central role of the propensity score in observational studies for causal effects. Biometrika, 70(1), 41–55.CrossRef
34.
go back to reference Devilliers, H., Amoura, Z., Besancenot, J.-F., Bonnotte, B., Pasquali, J.-L., Wahl, D., et al. (2014). Responsiveness of the 36-item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLE. Rheumatology, 54, 940–949CrossRefPubMed Devilliers, H., Amoura, Z., Besancenot, J.-F., Bonnotte, B., Pasquali, J.-L., Wahl, D., et al. (2014). Responsiveness of the 36-item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLE. Rheumatology, 54, 940–949CrossRefPubMed
35.
go back to reference Rigby, W., Ferraccioli, G., Greenwald, M., Zazueta-Montiel, B., Fleischmann, R., Wassenberg, S., et al. (2011). Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care and Research, 63(5), 711–720.CrossRefPubMed Rigby, W., Ferraccioli, G., Greenwald, M., Zazueta-Montiel, B., Fleischmann, R., Wassenberg, S., et al. (2011). Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care and Research, 63(5), 711–720.CrossRefPubMed
36.
go back to reference Kosinski, M., Zhao, S. Z., Dedhiya, S., Osterhaus, J. T., & Ware, J. E. (2000). Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis and rheumatism, 43(7), 1478–1487.CrossRefPubMed Kosinski, M., Zhao, S. Z., Dedhiya, S., Osterhaus, J. T., & Ware, J. E. (2000). Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis and rheumatism, 43(7), 1478–1487.CrossRefPubMed
37.
go back to reference Colangelo, K. J., Pope, J. E., & Peschken, C. (2009). The minimally important difference for patient reported outcomes in systemic lupus erythematosus including the HAQ-DI, pain, fatigue, and SF-36. The Journal of Rheumatology, 36(10), 2231–2237.CrossRefPubMed Colangelo, K. J., Pope, J. E., & Peschken, C. (2009). The minimally important difference for patient reported outcomes in systemic lupus erythematosus including the HAQ-DI, pain, fatigue, and SF-36. The Journal of Rheumatology, 36(10), 2231–2237.CrossRefPubMed
38.
go back to reference Yen, J. C., Abrahamowicz, M., Dobkin, P. L., Clarke, A. E., Battista, R. N., & Fortin, P. R. (2003). Determinants of discordance between patients and physicians in their assessment of lupus disease activity. The Journal of Rheumatology, 30(9), 1967–1976.PubMed Yen, J. C., Abrahamowicz, M., Dobkin, P. L., Clarke, A. E., Battista, R. N., & Fortin, P. R. (2003). Determinants of discordance between patients and physicians in their assessment of lupus disease activity. The Journal of Rheumatology, 30(9), 1967–1976.PubMed
39.
go back to reference Neville, C., Clarke, A. E., Joseph, L., Belisle, P., Ferland, D., & Fortin, P. R. (2000). Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity. The Journal of Rheumatology, 27(3), 675–679.PubMed Neville, C., Clarke, A. E., Joseph, L., Belisle, P., Ferland, D., & Fortin, P. R. (2000). Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity. The Journal of Rheumatology, 27(3), 675–679.PubMed
41.
go back to reference Dua, A. B., Touma, Z., Toloza, S., & Jolly, M. (2013). Top 10 recent developments in health-related quality of life in patients with systemic lupus erythematosus. Current Rheumatology Reports, 15(12), 380.CrossRefPubMed Dua, A. B., Touma, Z., Toloza, S., & Jolly, M. (2013). Top 10 recent developments in health-related quality of life in patients with systemic lupus erythematosus. Current Rheumatology Reports, 15(12), 380.CrossRefPubMed
Metagegevens
Titel
Differential impact of systemic lupus erythematosus and rheumatoid arthritis on health-related quality of life
Auteurs
Benjamin Chaigne
Axel Finckh
Deshire Alpizar-Rodriguez
Delphine Courvoisier
Camillo Ribi
Carlo Chizzolini
For The Swiss Clinical Quality Management Program For Rheumatoid Arthritis
The Swiss Systemic Lupus Erythematosus Cohort Study Group
Publicatiedatum
11-03-2017
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 7/2017
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-017-1534-4

Andere artikelen Uitgave 7/2017

Quality of Life Research 7/2017 Naar de uitgave